Related Experiment Video

Updated: Jun 13, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Smoking at least 10 cigarettes per day increases platelet inhibition by clopidogrel in patients with

Young-Hoon Jeong1, Jung-Hyun Cho, Min-Kyung Kang

  • 1Division of Cardiology, Department of Internal Medicine, Gyeongsang National University Hospital, 90 Chiram-dong, Jinju, 660-702, Gyeongsangnam-do, South Korea. goodoctor@naver.com

Thrombosis Research
|May 11, 2010
PubMed

Insights

Cigarette smoking (CS) significantly enhances clopidogrel

Area of Science:

  • Cardiology
  • Pharmacology
  • Thrombosis

Background:

  • Emerging data suggest cigarette smoking (CS) may reduce cardiovascular event risk in ST-segment-elevation myocardial infarction (STEMI) patients.
  • The mechanism may involve CS affecting clopidogrel metabolism, but the dose-response relationship with clopidogrel's antiplatelet effect is unclear.

Purpose of the Study:

  • To investigate the association between the extent of cigarette smoking (CS) and clopidogrel-induced platelet inhibition.
  • To determine if smoking status influences platelet reactivity in healthy subjects and STEMI patients treated with clopidogrel.

Main Methods:

  • Assessed inhibition of platelet aggregation (IPA) in 20 healthy subjects after a 600-mg clopidogrel load.
  • Evaluated on-clopidogrel platelet reactivity (PR) using aggregometry and VerifyNow P2Y(12) in 138 STEMI patients, stratified by smoking status.

Main Results:

  • In healthy subjects, smoking ≥10 cigarettes/day correlated with higher IPA.
  • STEMI patients smoking ≥10 cigarettes/day showed significantly lower PR (5 & 20 μmol/L ADP) and P2Y(12) reaction units compared to non-smokers.
  • Heavy smoking (≥10 cigarettes/day) was the sole predictor of low on-clopidogrel PR in multivariate analysis.

Conclusions:

  • Cigarette smoking appears to augment the antiplatelet response to clopidogrel in both healthy individuals and STEMI patients.
  • Smoking 10 or more cigarettes daily significantly reduces platelet reactivity to clopidogrel in these populations.
Abstract

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...